Related literature data confirm that ACVRL1 mutation carriers carrying PAH have dominant mutations in exon 10, especially in NANDOR boxes, which are essential for the regulation of TGF-β signaling (Harrison et al., 2005; Girerd et al., 2010). Here, ACVRL1 is linked to pulmonary arterial hypertension.